A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Submitted by admin on December 1, 2022 - 10:34am

Source:

Medical Marketing and Media

News Tags:

CSL

Hemgenix

drug pricing

hemophila B

Headline:

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

snippet:

The Food and Drug Administration approved CSL Behring’s hemophilia B drug Hemgenix (also known as EtranaDez) last week, the first-ever gene therapy for the disease.

Its one-time cost of $3.5 million set a new benchmark as the highest price for any drug.

Search form

You are here

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount